Abstract:the of in various serotypes a the capsid internal that determine the internal of 22 eukaryotic viruses with icosahedral symmetry including that belong to the family of Parvoviridae. In addition, we the maximal packaging capacity of both capsids and VP3 only capsids from various serotypes using a of recombinant AAV2 vector genomes of varying sizes from 4.80 kb up to 6.00 kb by an increment of 0.05 kb, ruler genomes. determine capsid internal volumes, three dimensional structure coordinates of each viral capsid were from the Protein Data Bank, and an we each a interstices between adjacent atoms in the protein are effectively filled the of the inner surface of the capsid The of capsid a numerical integration of in the to the center than the atom that is most distant from the center of the capsid. By this method, we find that the genome lengths and internal volumes of the 22 eukaryotic T=1 viruses that we analyzed vary from 0.83 kb to 6.04 kb and from 6.72 x 10 5 to 3.46 x 10 6 Å 3 , respectively, showing a strong non-linear allometric relationship with an exponent of 1.30 (R 2 =0.97). In the following AAV serotypes, AAV1, 2, 3B, 4, 5, 6, 8 and 9, AAV5 is found to have a distinctively smaller volume (2.48 x 10 6 Å 3 ) compared to the other 7 serotypes (2.62 ± 0.03 x 10 6 Å 3 , mean ± SD). This analysis also reveals that AAV2 VP3 only capsid has a 7% larger volume than AAV2 VP1/VP2/VP3 capsid. In keeping with this observation, a preliminary study using the ruler genomes has indicated that the AAV2 VP3 capsid can package a genome that is longer than that can be packaged in the AAV2 VP1/VP2/VP3 capsid by several hundred nucleotides, which appears to correspond to the difference in the volume of the two different capsids. Investigation of other serotypes and capsid mutants is currently underway. Thus, the approach presented here will help understand the genome packaging and provide insights into how to design capsids to overcome packaging limitations. Vector dose-related toxicity has been highlighted as a potential safety concern in recent preclinical studies and clinical trials with recombinant AAV vectors. Thus, investigation of strategies to enhance AAV transduction may allow for administration of lower vector doses, thereby mitigating toxicity. Several host cell factors have been shown to restrict viral infection during post-entry trafficking steps through a variety of mechanisms. the overexpression of ERI-1 determined an over 10-fold, selective reduction on ssAAV genome association with H3 and H4, while changes were negligible for scAAV DNA and for control cellular genes. Consistent with chromatin exerting a repressive role on ssAAV transduction, we also noticed downregulation of replication-dependent chaperone induced over in transduction. decreased findings be development effective delivery strategies. of hepatic transgene product. Our suggest and reinforce the importance of Kupffer cells as key APCs for hepatic antigens and further characterize the impact of the route of antigen expression on T cell activation and Treg induction.

Recombinant AAV Genome Size Effect on Viral Vector Production, Purification, and Thermostability

Characterization of genome integrity for oversized recombinant AAV vector.

AAV Biology 37. Capacity of Viral Genome Packaging and Internal Volumes of AAV Viral Particles Trafficking as a Strategy to Enhance Recombinant AAV Transduction

Effects of Thermally Induced Configuration Changes on Raav Genome's Enzymatic Accessibility.

505. Analysis of AAV Genome Conversion and Stabilization

Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation Vs. Immuno-Affinity Chromatography.

Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production

Probing recombinant AAV capsid integrity and genome release after thermal stress by mass photometry

Human and Insect Cell-Produced Recombinant Adeno-Associated Viruses Show Differences in Genome Heterogeneity

Accurate Quantification of AAV Vector Genomes by Quantitative PCR

Proteomic Landscape of Adeno-Associated Virus (AAV)-Producing HEK293 Cells

Process Improvement of Adeno-Associated Virus Production

Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

The Role of Thermal Stability in AAV Titration of Engineered Variants

A Comprehensive Study of the Effects by Sequence Truncation within Inverted Terminal Repeats (ITRs) on the Productivity, Genome Packaging, and Potency of AAV Vectors

High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions

Orthogonal characterization of rAAV9 reveals unexpected transgene heterogeneity

Production of High-Yield Adeno Associated Vector Batches Using HEK293 Suspension Cells

9. rAAV Designs Harboring DNA Secondary Structures with High Thermal Stabilities Produce Heterogenic Viral Genome Populations

Assessment of Key Factors Impacting Variability in AAV Vector Genome Titration by Digital PCR

Enhancing the production of adeno‐associated virus (AAV)2 and AAV9 with high full capsid ratio in HEK293 cells through design‐of‐experiment optimization of triple plasmid ratio